RP-HPLC

Background: Simultaneous analysis of drug combinations requires prior understanding of the individual physicochemical and spectroscopic behavior of each analyte and systematic optimization of chromatographic selectivity. Indapamide (IND), a thiazide-like diuretic, and losartan potassium (LOS), an angiotensin II receptor blocker, differ markedly in aqueous solubility, lipophilicity and UV absorption behavior. Objective: The present work profiled IND and LOS by preliminary physicochemical tests, FTIR, UV–visible spectrophotometry and RP-HPLC to establish analytical conditions suitable for simultaneous determination. Methods: Melting point and solubility were evaluated, FTIR spectra were interpreted for characteristic functional groups, and methanolic UV spectra were scanned from 200–400 nm. Chromatographic screening was performed on a C18 column (250 × 4.6 mm, 5 µm) using seven mobile-phase trials. Results: IND showed a melting point of 163–165°C and LOS 262–264°C. Characteristic FTIR bands supported identity of both analytes. UV maxima were approximately 236 nm for IND and 206 nm for LOS; an overlay supported 214 nm as the common HPLC detection wavelength. The optimized chromatographic system consisted of phosphate buffer pH 3.0:acetonitrile (40:60, v/v) at 1.0 mL/min. IND and LOS eluted at approximately 3.74 and 6.98 min, respectively, with a resolution of 11.22. Calibration responses were linear over 0.75–7.5 µg/mL for IND and 25–250 µg/mL for LOS, with R² values of 0.9997 and 0.9996. Conclusion: Complementary UV, FTIR and chromatographic profiling provided a rational basis for simultaneous analysis of IND and LOS and established a selective RP-HPLC condition for their quantitative determination.

Animal models play a key role in personalized medicine because they help define the pharmacokinetics, pharmacodynamics, safety and therapeutic profile of conventional and nano-enabled drug delivery systems. In comparison to conventional dosage forms, current successful targeting and control of drug release are restricted, nano-enabled carriers improve solubility, extend systemic circulation and allow site specific delivery. Inter-individual variability in drug metabolism, enzyme, and immune response are also prominent with animal models, appropriate dose selection, safety testing, and formulations to make therapy more person-specific. High end techniques such as in vivo imaging, biodistribution analysis, histopathology, and toxicological screening enhance these studies in terms of translating their strength. By integrating both animal-based studies with biomarker-based methods, computational modeling, and complimentary in vitro methods, the accuracy of predictive methods increases dramatically. The studies highlight the imperativeness of animal research as mediator between the preclinical research and the clinical implementation, in the establishment of safe, effective, and custom designed pharmaceutic interventions in personal medicine.